Donald A Barkauskas

List of Publications by Year
in descending order

67	4,011	201674	123424
papers	citations	27 h-index	61 g-index

68	68	68	8461
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clinical Cancer Research, 2017, 23, 4242-4250.	7.0	704
2	Detectable clonal mosaicism and its relationship to aging and cancer. Nature Genetics, 2012, 44, 651-658.	21.4	519
3	Assessment of Plasma C-Reactive Protein as a Biomarker of Posttraumatic Stress Disorder Risk. JAMA Psychiatry, 2014, 71, 423.	11.0	290
4	Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nature Genetics, 2013, 45, 799-803.	21.4	181
5	Association Between Traumatic Brain Injury and Risk of Posttraumatic Stress Disorder in Active-Duty Marines. JAMA Psychiatry, 2014, 71, 149.	11.0	181
6	Rituximab for High-Risk, Mature B-Cell Non-Hodgkinâ€™s Lymphoma in Children. New England Journal of Medicine, 2020, 382, 2207-2219.	27.0	157
7	Outcome for adolescent and young adult patients with osteosarcoma. Cancer, 2012, 118, 4597-4605.	4.1	153
8	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. JAMA Oncology, 2020, 6, 724.	7.1	139
9	The cumulative effect of different childhood trauma types on self-reported symptoms of adult male depression and PTSD, substance abuse and health-related quality of life in a large active-duty military cohort. Journal of Psychiatric Research, 2014, 58, 46-54.	3.1	105
10	Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. Journal of Clinical Oncology, 2021, 39, 2859-2871.	1.6	101
11	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
12	A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. Cancer Discovery, 2015, 5, 920-931.	9.4	88
13	Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Childrenâ€™s Oncology Group. British Journal of Cancer, 2018, 119, 615-621.	6.4	83
14	Crossâ€species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Medicine, 2015, 4, 977-988.	2.8	69
15	Gene expression profiling of <scp>E</scp>wing sarcoma tumours reveals the prognostic importance of tumourâ€“stromal interactions: a report from the <scp>C</scp>hildren's <scp>O</scp>ncology <scp>G</scp>roup. Journal of Pathology: Clinical Research, 2015, 1, 83-94.	3.0	66
16	Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen.. Journal of Clinical Oncology, 2016, 34, 10507-10507.	1.6	62
17	A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). Clinical Cancer Research, 2019, 25, 3229-3238.	7.0	61
18	Germline Cancer Predisposition Variants inâ€, Pediatric Rhabdomyosarcoma: A Report From the Childrenâ€™s Oncology Group. Journal of the National Cancer Institute, 2021, 113, 875-883.	6.3	55

#	Article	IF	Citations
19	Circadian rhythmicity, variability and correlation of interleukin-6 levels in plasma and cerebrospinal fluid of healthy men. Psychoneuroendocrinology, 2014, 44, 71-82.	2.7	52
20	High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-NaÃ¯ve Patients with Diverse Cancers. Molecular Cancer Therapeutics, 2020, 19, 2139-2145.	4.1	50
21	Serum Glycan Signatures of Gastric Cancer. Cancer Prevention Research, 2014, 7, 226-235.	1.5	48
22	The serum immunoglobulin G glycosylation signature of gastric cancer. EuPA Open Proteomics, 2015, 6, 1-9.	2.5	45
23	Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma. Oncotarget, 2017, 8, 96738-96752.	1.8	41
24	Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood, 2021, 137, 3595-3603.	1.4	40
25	Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2019, 66, e27444.	1.5	33
26	High-BMI at diagnosis is associated with inferior survival in patients with osteosarcoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2013, 60, 2042-2046.	1.5	32
27	Genomeâ€wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. International Journal of Cancer, 2018, 142, 1594-1601.	5.1	31
28	Characterization of cerebrospinal fluid (CSF) and plasma NPY levels in normal volunteers over a 24-h timeframe. Psychoneuroendocrinology, 2013, 38, 2378-2382.	2.7	27
29	p27 Is a Candidate Prognostic Biomarker and Metastatic Promoter in Osteosarcoma. Cancer Research, 2016, 76, 4002-4011.	0.9	27
30	Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma. JCO Precision Oncology, 2021, 5, 75-87.	3.0	27
31	Predictive properties of DNA methylation patterns in primary tumor samples for osteosarcoma relapse status. Epigenetics, 2015, 10, 31-39.	2.7	26
32	A novel prognostic model for osteosarcoma using circulating <scp>CXCL</scp>10 and <scp>FLT</scp>3<scp>LG</scp>. Cancer, 2017, 123, 144-154.	4.1	26
33	Relations of combat stress and posttraumatic stress disorder to 24-h plasma and cerebrospinal fluid interleukin-6 levels and circadian rhythmicity. Psychoneuroendocrinology, 2019, 100, 237-245.	2.7	24
34	STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications. European Journal of Cancer, 2021, 148, 215-229.	2.8	24
35	HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. Pediatric Blood and Cancer, 2014, 61, 1558-1564.	1.5	23
36	Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. Clinical Cancer Research, 2016, 22, 3643-3650.	7.0	23

#	Article	IF	Citations
37	Investigation of the insulinâ€like growth factorâ€1 signaling pathway in localized Ewing sarcoma. Cancer, 2011, 117, 4966-4976.	4.1	21
38	Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups. Journal of Clinical Oncology, 2018, 36, 3466-3476.	1.6	21
39	Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PDâ€L1 expression in cancer patients. International Journal of Cancer, 2020, 146, 3087-3097.	5.1	20
40	Stress-Induced Isoforms of MDM2 and MDM4 Correlate with High-Grade Disease and an Altered Splicing Network in Pediatric Rhabdomyosarcoma. Neoplasia, 2013, 15, 1049-IN8.	5.3	19
41	Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcomaâ€"Associations with tumor phenotype and survival. Cancer, 2015, 121, 697-707.	4.1	19
42	A general-purpose baseline estimation algorithm for spectroscopic data. Analytica Chimica Acta, 2010, 657, 191-197.	5.4	18
43	Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial. Journal of Clinical Oncology, 2021, 39, 3716-3724.	1.6	18
44	ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcomaâ€"A Children's Oncology Group study. Cancer, 2020, 126, 5303-5310.	4.1	17
45	Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. OncoImmunology, 2020, 9, 1710052.	4.6	17
46	Prospective Associations Between Traumatic Brain Injury and Postdeployment Tinnitus in Active-Duty Marines. Journal of Head Trauma Rehabilitation, 2016, 31, 30-39.	1.7	14
47	Targeting fusions for improved outcomes in oncology treatment. Cancer, 2020, 126, 1315-1321.	4.1	14
48	Analysis of MALDI FT-ICR mass spectrometry data: A time series approach. Analytica Chimica Acta, 2009, 648, 207-214.	5.4	13
49	Centralizers in graph products of groups. Journal of Algebra, 2007, 312, 9-32.	0.7	10
50	Phase 2 trial of cabozantinib in children and young adults with refractory sarcomas, Wilms tumor, and rare tumors: Children's Oncology Group Study (ADVL1622).. Journal of Clinical Oncology, 2021, 39, 10010-10010.	1.6	10
51	Deep Learning of Rhabdomyosarcoma Pathology Images for Classification and Survival Outcome Prediction. American Journal of Pathology, 2022, 192, 917-925.	3.8	10
52	Analysis of serum insulin growth factorâ€1 concentrations in localized osteosarcoma: A children's oncology group study. Pediatric Blood and Cancer, 2014, 61, 749-752.	1.5	9
53	Targeted resequencing of pediatric rhabdomyosarcoma: report from the Childrenâ€™s Oncology Group, the Childrenâ€™s Cancer and Leukaemia Group, The Institute of Cancer Research UK, and the National Cancer Institute.. Journal of Clinical Oncology, 2018, 36, 10515-10515.	1.6	9
54	Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: A report from the Children's Oncology Group and the QuadW Foundation. PLoS ONE, 2017, 12, e0181204.	2.5	8

#	Article	IF	Citations
55	Tumor mutational burden is not predictive of cytotoxic chemotherapy response. OncoImmunology, 2020, 9, 1781997.	4.6	8
56	Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Childrenâ€™s Oncology Group Study ADVL06B1. Cancer Chemotherapy and Pharmacology, 2021, 88, 359-365.	2.3	7
57	Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma. Sarcoma, 2021, 2021, 1-10.	1.3	6
58	BRAF V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes. Molecular Cancer Therapeutics, 2021, 20, 1072-1079.	4.1	6
59	MEK Inhibition Demonstrates Activity in Relapsed, Refractory Patients with Juvenile Myelomonocytic Leukemia: Results from COG Study ADVL1521. Blood, 2021, 138, 3679-3679.	1.4	4
60	The prognostic significance of circulating serum amyloid A and CXC chemokine ligand 4 in osteosarcoma. Pediatric Blood and Cancer, 2017, 64, e26659.	1.5	3
61	Toxicity Profile of Brentuximab Vedotin in Combination with Chemotherapy for Newly Diagnosed Patients with ALK+ ALCL: A Children's Oncology Group Study ANHL12P1. Blood, 2018, 132, 1625-1625.	1.4	2
62	Rhabdomyosarcoma Histology Classification using Ensemble of Deep Learning Networks. , 2020, , .		2
63	The Childrenâ€™s Oncology Group and QuadW Foundation osteosarcoma banking experience.. Journal of Clinical Oncology, 2013, 31, 10053-10053.	1.6	0
64	Meta-analysis of effects of demographic and treatment variables on outcome for localized paratesticular rhabdomyosarcoma (PT RMS) in North America and Europe.. Journal of Clinical Oncology, 2015, 33, 10044-10044.	1.6	0
65	Complete dexrazoxane cardioprotection for cardiac function but incomplete female cardioprotection for cardiac structure in doxorubicin-treated osteosarcoma survivors: Hearts too small for the body.. Journal of Clinical Oncology, 2017, 35, 10519-10519.	1.6	0
66	Can DNA methylation patterns be used as predictive biomarkers for chemotherapy response in osteosarcoma?. Journal of Clinical Oncology, 2018, 36, 11525-11525.	1.6	0
67	Reply to R. Lakhotia et al. Journal of Clinical Oncology, 2022, , JCO2102912.	1.6	0